Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the safety and efficacy of BLI-801 administered at 4 dose levels in constipated adults.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | BLI-801 Dose 1 |
|
| 2 | Experimental | BLI-801 Dose 2 |
|
| 3 | Experimental | BLI-801 Dose 3 |
|
| 4 | Experimental | BLI-801 Dose 4 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BLI-801 | Drug | Dose 1 |
| |
| BLI-801 |
| Measure | Description | Time Frame |
|---|---|---|
| Bowel Movement Count | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events | 24 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John McGowan | Braintree Laboratories, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim | California | United States | ||||
Not provided
| ID | Term |
|---|---|
| D003248 | Constipation |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Dose 2 |
|
| BLI-801 | Drug | Dose 3 |
|
| BLI-801 | Drug | Dose 4 |
|
| Cranston |
| Rhode Island |
| United States |
| Cumberland | Rhode Island | United States |